Number of patients N=749 | Per cent | |
---|---|---|
Sex | ||
Male | 503 | 67.2 |
Transmission risk group | ||
Heterosexual | 386 | 51.5 |
MSM | 312 | 41.7 |
IDU | 23 | 3.1 |
Blood product | 7 | 0.9 |
Unknown | 21 | 2.8 |
Ethnicity | ||
Black African | 228 | 30.4 |
White | 441 | 58.9 |
Other | 80 | 10.7 |
Age (years) (median, IQR) | 42.2 | (35.5–49.4) |
Age category (years) | ||
18–39 | 310 | 41.4 |
40–49 | 265 | 35.4 |
50–59 | 118 | 15.8 |
60+ | 56 | 7.5 |
Treatment status | ||
On ART | 612 | 81.7 |
Started ART pre 01/01/2003 | 168 | 22.4 |
Viral load (copies per ml) | ||
Treated and suppressed (vl≤50) | 535 | 71.4 |
Treated and unsuppressed | 77 | 10.3 |
Untreated | 137 | 18.3 |
Median CD4 count (mm3), untreated (IQR) | 477 | (334–602) |
Median CD4 count (mm3), treated (IQR) | 559.5 | (409–721) |
CD4 count (mm3) | ||
<500 | 318 | 42.5 |
500–749 | 275 | 36.7 |
≥750 | 156 | 20.8 |
Median total cholesterol(mg/dL) (IQR) | 189.1 | (162–220) |
Median HDL cholesterol(mg/dL) (IQR) | 50.2 | (38.6–61.8) |
Median systolic blood pressure(mmHg) (IQR) | 131 | (117–143) |
ART, antiretroviral therapy; HDL, high-density lipoprotein; IDU,injection drug use; IQR, interquartile range; MSM, men who have sex with men.